Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future
Type 1 diabetes treatment stands at a crucial and exciting crossroad since the 2022 U.S. Food and Drug Administration approval of teplizumab to delay disease development. In this article, we discuss four major conceptual and practical issues that emerged as key to further advancement in type 1 diabetes research and therapies. First, collaborative networks leveraging the synergy between the type 1 diabetes research and care community members are key to fostering innovation, know-how, and translation into the clinical arena worldwide. Second, recent clinical trials in presymptomatic stage 2 and recent-onset stage 3 disease have shown the promise, and potential pitfalls, of using immunomodulatory and/or β-cell protective agents to achieve sustained remission or prevention. Third, the increasingly appreciated heterogeneity of clinical, immunological, and metabolic phenotypes and disease trajectories is of critical importance to advance the decision-making process for tailored type 1 diabetes care and therapy. Fourth, the clinical benefits of early diagnosis of β-cell autoimmunity warrant consideration of general population screening for islet autoantibodies, which requires further efforts to address the technical, organizational, and ethical challenges inherent to a sustainable program. Efforts are underway to integrate these four concepts into the future directions of type 1 diabetes research and therapy. Article Highlights
Authors
- Peter Achenbach (ORCID: https://orcid.org/0000-0001-6720-2684)
- Alberto Pugliese (ORCID: https://orcid.org/0000-0002-7211-0319)
- Emily K. Sims (ORCID: https://orcid.org/0000-0002-4393-954X)
- David Klatzmann (ORCID: https://orcid.org/0000-0002-0054-3422)
- Sylvaine You (ORCID: https://orcid.org/0000-0002-1578-5205)
- Roberto Mallone (ORCID: https://orcid.org/0000-0002-9846-8861)
- Chantal Mathieu (ORCID: https://orcid.org/0000-0002-4055-5233)
- S. Alice Long (ORCID: https://orcid.org/0000-0002-0281-1240)
- Mark A. Atkinson (ORCID: https://orcid.org/0000-0001-8489-4782)
- Teresa Rodríguez-Calvo (ORCID: https://orcid.org/0000-0003-1531-8583)
- Anette‐Gabriele Ziegler (ORCID: https://orcid.org/0000-0002-6290-5548)
- Carmella Evans‐Molina (ORCID: https://orcid.org/0000-0001-7764-8663)
- Anne Koralova
- L. Overbergh
- Sanjoy Dutta (ORCID: https://orcid.org/0000-0001-8117-1677)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Center for Infectious Disease Research (US)
- Inserm (FR)
- Université Paris Cité (FR)
- Leona M. and Harry B. Helmsley Charitable Trust (US)
- Indiana Biosciences Research Institute (US)
- Center for Environmental Health (US)
- Helmholtz Zentrum München (DE)
- University of Florida (US)
- Sorbonne Université (FR)
- Hôpital Cochin (FR)
- Breakthrough T1D (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Richard L. Roudebush VA Medical Center (US)
- City of Hope (US)
- Pitié-Salpêtrière Hospital (FR)
- Bipar (FR)
- Institut Cochin (FR)
- German Center for Diabetes Research (DE)
- Immunologie - Immunopathologie - Immunothérapie (FR)
- Beckman Research Institute
- Benaroya Research Institute
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
- Florida College (US)
- KU Leuven (BE)
Publication Details
- Journal
- Diabetes
- Published
- 2024-10-24
- DOI
- https://doi.org/10.2337/db24-0439
- Citations
- 6
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 3.44